References
- Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006–2013.
- Vandyke K, Fitter S, Dewar AL, et al. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010;115:766–774.
- O’Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679–1689.
- Brownlow N, Russell AE, Saravanapavan H, et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 2008;22:649–652.
- Tibullo D, Giallongo C, La Cava P, et al. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009;37:461–468.
- Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;111:2538–2547.
- Jönsson S, Olsson B, Ohlsson C, et al. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008;93:1101–1103.
- Jönsson S, Standal T, Olsson B, Mellström D, Wadenvik H. Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib. Am J Hematol 2012;87:550–552.
- O’Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009;94:1131–1136.
- O’Sullivan S, Horne A, Wattie D, et al. Bone metabolism during long-term treatment with imatinib. Leuk Lymphoma 2013;1783–1785.
- O’Sullivan S, Naot D, Callon KE, et al. Imatinib mesylate does not increase bone volume in vivo. Calcif Tissue Int 2011;88:16–22.
- Jönsson S, Hjorth-Hansen H, Olsson B, et al. Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. J Bone Miner Metab 2012;30:119–123.